# Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Source: https://onco.cc/trials/nct06508931/  
OnCo record `nct06508931` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zamtocabtagene autoleucel in advanced solid tumours, run by Miltenyi Biomedicine GmbH, now recruiting.

## Summary

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms is a phase 2 interventional study registered as NCT06508931 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-08-04 and due to reach its primary completion in 2029-12-31. Interventions recorded: zamtocabtagene autoleucel (MB-CART2019.1).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06508931
- Phase: 2
- Setting: A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease
- Sponsor: Miltenyi Biomedicine GmbH
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT06508931: https://clinicaltrials.gov/study/NCT06508931

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Zamtocabtagene autoleucel](https://onco.cc/drugs/zamtocabtagene-autoleucel/)
- companies: [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/)

---
JSON: https://onco.cc/api/v1/entities/nct06508931.json